Skip to main content
Top
Published in: Annals of Hematology 9/2003

01-09-2003 | Original Article

Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution

Authors: C. Lass-Flörl, E. Gunsilius, G. Gastl, M. Englisch, G. Koch, H. Ulmer, M. P. Dierich, A. Petzer

Published in: Annals of Hematology | Issue 9/2003

Login to get access

Abstract

We assessed the impact of prophylaxis with the oral itraconazole solution and amphotericin B solution on fungal colonization and infection in a randomized study among patients with hematological malignancies and neutropenia. Infecting and colonizing Candida strains of patients suffering from candidiasis were genotyped by random amplification of polymorphic DNA (RAPD) analysis. A total of 106 patients were evaluated in this study: 52 patients in the itraconazole and 54 in the amphotericin B arm. During neutropenia fungal colonization in the oropharynx occurred in 11 (19.6%) and 24 (40.6%) and in the rectum in 11 (19.6%) and 23 (38.9%) courses in the itraconazole and amphotericin B groups (P<0.05), respectively. Candida albicans was the most prevalent species in both study groups. Mixed fungal colonization with Candida krusei and Candida glabrata was increased in the amphotericin B group, yet without clinical importance since infections were due to C. albicans. The occurrence of invasive candidiasis was significantly increased in multicolonized compared to monocolonized patients. In the amphotericin B group 20 and in the itraconazole group 2 neutropenic patients showed multicolonization with Candida spp. (P<0.05). Overall fungal infections were 3.8% in the itraconazole and 14.8% in the amphotericin B group (P<0.05). RAPD typing showed oropharynx strains involved in superficial infections in four of five patients. In all four patients with deep fungal infections, it appears that the colonizing rectum strains were identical to infecting strains of Candida spp. Itraconazole solution significantly reduced Candida colonization and infection compared to amphotericin B solution. Most patients remained infected with the colonized strains for the entire study period, irrespective of antifungal prophylaxis.
Literature
1.
go back to reference Denning D, Legrand P, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Cantanzaro A (1994) NIAID Mycosis Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 97:135–144 Denning D, Legrand P, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Cantanzaro A (1994) NIAID Mycosis Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 97:135–144
2.
go back to reference Denning DW (1991) Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J Antimicrob Chemother 28 [Suppl B]:1–16 Denning DW (1991) Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J Antimicrob Chemother 28 [Suppl B]:1–16
3.
go back to reference Bodey GP, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, Mall G, Martino P, Meunier F, Milliken S (1992) Fungal infections in cancer patients: an international autopsy study. Eur J Clin Microbiol Infect Dis 11:99–109PubMed Bodey GP, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, Mall G, Martino P, Meunier F, Milliken S (1992) Fungal infections in cancer patients: an international autopsy study. Eur J Clin Microbiol Infect Dis 11:99–109PubMed
4.
go back to reference Kullberg B, Lashof O (2002) Epidemiology of opportunistic invasive mycoses. Eur J Med Res 7:183–191PubMed Kullberg B, Lashof O (2002) Epidemiology of opportunistic invasive mycoses. Eur J Med Res 7:183–191PubMed
5.
go back to reference Pfaffenbach B, Donhuijsen K, Pahnke J, Bug R, Adamek RJ, Wege M, Ricken D (1994) Systemic fungal infections in hematologic neoplasms. An autopsy study of 1053 patients. Med Klin 89:299–304PubMed Pfaffenbach B, Donhuijsen K, Pahnke J, Bug R, Adamek RJ, Wege M, Ricken D (1994) Systemic fungal infections in hematologic neoplasms. An autopsy study of 1053 patients. Med Klin 89:299–304PubMed
6.
go back to reference Anaissie E, Bodey GP (1989) Nosocomial fungal infections. Old problems and new challenges. Infect Dis Clin North Am 3:867–882PubMed Anaissie E, Bodey GP (1989) Nosocomial fungal infections. Old problems and new challenges. Infect Dis Clin North Am 3:867–882PubMed
7.
go back to reference Inoue S, Wirman JA, Alexander JW, Trocki O, Cardell RR (1988) Candida albicans translocation across the gut mucosa following burn injury. J Surg Res 44:479–492PubMed Inoue S, Wirman JA, Alexander JW, Trocki O, Cardell RR (1988) Candida albicans translocation across the gut mucosa following burn injury. J Surg Res 44:479–492PubMed
8.
go back to reference Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, Powderly WG, Silber J, Horowitz H, Lichtin A (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326:845–851PubMed Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, Powderly WG, Silber J, Horowitz H, Lichtin A (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326:845–851PubMed
9.
go back to reference Meunier F (1987) Prevention and mycoses in immunocompromised patients. Rev Infect Dis 9:408–416PubMed Meunier F (1987) Prevention and mycoses in immunocompromised patients. Rev Infect Dis 9:408–416PubMed
10.
go back to reference Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, Shadduck RK, Rosenfeld CS, Ho WG, Islam MZ, Buell DN (1993) Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Ann Intern Med 118:495–503PubMed Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, Shadduck RK, Rosenfeld CS, Ho WG, Islam MZ, Buell DN (1993) Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Ann Intern Med 118:495–503PubMed
11.
go back to reference Harousseau J, Dekker AW, Stamatoullas-Bastard A, Fassas A, Linkesch W, Gouveia J, DeBock R, Rovira M, Seifert WF, Joosen H, Peeters M, DeBeule K (2000) Itraconazole oral solution for primary prophylaxis of fungal infections in patients wit hematological malignancy and profound neutropenia: a randomized, double-blind, double placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 44:1887–1893PubMed Harousseau J, Dekker AW, Stamatoullas-Bastard A, Fassas A, Linkesch W, Gouveia J, DeBock R, Rovira M, Seifert WF, Joosen H, Peeters M, DeBeule K (2000) Itraconazole oral solution for primary prophylaxis of fungal infections in patients wit hematological malignancy and profound neutropenia: a randomized, double-blind, double placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 44:1887–1893PubMed
12.
go back to reference Böhme A, Just-Nübling G, Bergman L, Shah PM, Stille W, Hoelzer D (1996) Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with hematological malignancies. J Antimicrob Chemother 38:953–961 Böhme A, Just-Nübling G, Bergman L, Shah PM, Stille W, Hoelzer D (1996) Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with hematological malignancies. J Antimicrob Chemother 38:953–961
13.
go back to reference National Committee for Clinical Laboratory Standards (1997) Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. NCCLS, Villanova, PA, USA National Committee for Clinical Laboratory Standards (1997) Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. NCCLS, Villanova, PA, USA
14.
go back to reference Metzgar D, van Belkum A, Field D, Haubrich R, Wills C (1998) Random amplification of polymorphic DNA and microsatellite genotyping of pre- and posttreatment isolates of Candida spp. from human immunodeficiency virus-infected patients on different fluconazole regimens. J Clin Microbiol 36:2308-2313 Metzgar D, van Belkum A, Field D, Haubrich R, Wills C (1998) Random amplification of polymorphic DNA and microsatellite genotyping of pre- and posttreatment isolates of Candida spp. from human immunodeficiency virus-infected patients on different fluconazole regimens. J Clin Microbiol 36:2308-2313
15.
go back to reference Glasmacher A, Hahn C, Molitor E, Sauerbruch T, Schmidt-Wolf I, Marklein G (1999) Fungal surveillance cultures during antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Mycoses 42:395–402CrossRefPubMed Glasmacher A, Hahn C, Molitor E, Sauerbruch T, Schmidt-Wolf I, Marklein G (1999) Fungal surveillance cultures during antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Mycoses 42:395–402CrossRefPubMed
16.
go back to reference Vreugdenhil G, Van Dijke J, Donnelly JP, Novakova IR, Raemaekers JM, Hoogkamp-Korstanje JA, Koster M, de Bauw BE (1993) Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 11:353–358PubMed Vreugdenhil G, Van Dijke J, Donnelly JP, Novakova IR, Raemaekers JM, Hoogkamp-Korstanje JA, Koster M, de Bauw BE (1993) Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 11:353–358PubMed
17.
go back to reference Beck-Sague CM, Jarvis WR (1993) Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990. The National Nosocomial Infections Surveillance System. J Infect Dis 167:1247–1251PubMed Beck-Sague CM, Jarvis WR (1993) Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990. The National Nosocomial Infections Surveillance System. J Infect Dis 167:1247–1251PubMed
18.
go back to reference Nucci M, Anaissie, E (2001) Revisiting the source of candidemia: skin or gut? Clin Infect Dis 33:1959–1967 Nucci M, Anaissie, E (2001) Revisiting the source of candidemia: skin or gut? Clin Infect Dis 33:1959–1967
19.
go back to reference Cole G, Halawa A, Anaissie E (1996) The role of gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin Infect Dis 22 [Suppl 2]:73–88 Cole G, Halawa A, Anaissie E (1996) The role of gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin Infect Dis 22 [Suppl 2]:73–88
20.
go back to reference Bjorson H, Colley R, Bower R, Duty V, Schwartz-Fulton J, Fischer J (1982) Association between microorganism growth at the catheter insertion site and colonization of the catheter in patients receiving total parenteral nutrition. Surgery 92:720–727PubMed Bjorson H, Colley R, Bower R, Duty V, Schwartz-Fulton J, Fischer J (1982) Association between microorganism growth at the catheter insertion site and colonization of the catheter in patients receiving total parenteral nutrition. Surgery 92:720–727PubMed
21.
go back to reference Marr K, Seidel K, White T, Bowden R (2000) Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after adoption of prophylactic fluconazole. J Infect Dis 181:309–316PubMed Marr K, Seidel K, White T, Bowden R (2000) Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after adoption of prophylactic fluconazole. J Infect Dis 181:309–316PubMed
22.
go back to reference Lass-Flörl C, Nagl M, Speth C, Ulmer H, Dierich MP, Würzner R (2001) Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob Agents Chemother 45:124–128CrossRefPubMed Lass-Flörl C, Nagl M, Speth C, Ulmer H, Dierich MP, Würzner R (2001) Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob Agents Chemother 45:124–128CrossRefPubMed
23.
go back to reference Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C, Barbabietola G, Pagano L, Leoni P, Specchia G, Caiozzo A, Raimondi R, Mandelli F (1999) Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 28:250–255PubMed Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C, Barbabietola G, Pagano L, Leoni P, Specchia G, Caiozzo A, Raimondi R, Mandelli F (1999) Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 28:250–255PubMed
24.
go back to reference Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C, Sauerbruch T, Marklein G, Schmidt-Wolf I (1999) Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 42:443–451CrossRefPubMed Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C, Sauerbruch T, Marklein G, Schmidt-Wolf I (1999) Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 42:443–451CrossRefPubMed
Metadata
Title
Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution
Authors
C. Lass-Flörl
E. Gunsilius
G. Gastl
M. Englisch
G. Koch
H. Ulmer
M. P. Dierich
A. Petzer
Publication date
01-09-2003
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 9/2003
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-003-0666-5

Other articles of this Issue 9/2003

Annals of Hematology 9/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine